Brief: PDS Biotech Achieves Extended Survival In Low PD-L1 Expression Cohort In VERSATILE-002 Trial For Head & Neck Cancer
18/09/2025 13:51
Sept 18 (Reuters) - PDS Biotechnology Corp PDSB.O: PDS BIOTECH: ACHIEVES EXTENDED SURVIVAL IN LOW PD-L1 EXPRESSION COHORT IN VERSATILE-002 TRIAL FOR HEAD & NECK CANCER, POSSIBLY REMOVING NEED FOR CHEMO ((Reuters.Briefs@thomsonreuters.com;))
Recent news on PDS Biotechnology
See all newsPDS Biotechnology Corp reports results for the quarter ended September 30 - Earnings Summary
PDS Biotechnology Q3 net loss narrows on lower R&D costs
PDS Biotechnology Corp expected to post a loss of 10 cents a share - Earnings Preview
Brief: PDS Biotech Announces Initial Closing Of Up To $22.3 Mln PIPE Financing
Brief: Pds Biotechnology Corp - On Aug 6, Approved Reduction In Force To Align Expenses With Strategic Priorities - SEC Filing